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[Neuropsychopharmacology 10: [231] [232] [233] [234] [235] [236] [237] [238] 1994] for serotonin is 1170 IlmollL (Fowler and Tipton 1982; Garrick and Murphy 1982) . Monoamine oxidase A is inhibited by nanomolar concentrations of clorgyline (Johnston 1968) . Monoamine oxidase B (MAO-B) has a higher affinity for phenethylamine than MAO-A and is inhibited by nanomolar concentrations of deprenyl (Garrick and Murphy 1982; Yang and Neff 1974) . Dopa mine (DA) is metabolized with equal affinity by both subtypes (Yang and Neff 1974) . Further evidence for two molecular forms of MAO has been provided by the cloning of two distinct MAO genes (Bach et a1. 1988) and their subsequent functional expression in COS cells (Lan et a1. 1989) .
Both neurons and glia contain monoamine oxidases that catabolize the classical monoamine neurotransmit-ters. Monoamine oxidase A is the predominant form in catecholaminergic neurons, whereas MAO-B is the prevalent form in glia (Levitt et al. 1982; Westlund et al. 1985) . Although MAO-B has a higher affinity than MAO-B for serotonin, MAO-B is the major molecular form found within serotonergic neurons (Westlund et al. 1985) .
3, 4-Methylenedioxymethamphetamine (MDMA) binds with high affInity to the 5-HT transporter pro tein (Poblete et al. 1989 ) and has been shown to be a potent releaser of serotonin by a Ca 2 +-independent mechanism (Berger et al. 1992; Gu and Azmitia 1989; Johnson et al. 1986; Schmidt 1987; Schmidt et al. 1987) . MDMA has been demonstrated to produce a depletion of serotonin that may be reversed in acute stages by agents that bind to the serotonin transporter and block serotonin reuptake into presynaptic terminals (Azmitia et al. 1990; Schmidt 1987) . It also inhibits the 5-HT re uptake system (Steele et al. 1987) , resulting in an in creased amount of extracellular 5-HT. However, little attention has been paid to the fate of extracellular 5-HT.
Parachloroamphetamine (PCA) is another sub stituted amphetamine that is a potent releaser of sero tonin and has a biphasic depletion of serotonin similar to that observed with MDMA (Ask and Ross 1987; Berger et al. 1992; Fuller et al. 1975; Gu and Azmitia 1989; Gu 1993; Hwang and van Woert 1980; Mamounas and Molliver 1988; Poblete et al. 1989; Ross and Froden 1977) . As with MDMA, the depletion of serotonin resul tant from PCA may be reversed in its acute phase by serotonin uptake blockers (Fuller et al. 1975; . Parachloroamphetamine has been shown to in hibit MAO-A activity in rat brain homogenates with a Ki value of 1.31 IlmollL (Fuller 1966) . The toxicity of PCA is also affected by the amount of releasable sero tonin into the extracellular space. For instance, if sero tonin release is decreased by parachlorophenylalanine (pCP A) and reserpine, the level of toxicity is reduced (Berger et al. 1989) .
The anorectic compound, fenfluramine (FEN), is a halogenated amphetamine that has actions in serotonergic axon terminals similar to those of MDMA and PCA (Mamounas and Molliver 1988; Molliver and Molliver 1990; O'Hearn et al. 1988) . Like MDMA and PCA, FEN causes the release of 5-HT from presynaptic terminals (Borroni et al. 1983 ) and inhibits the reuptake of serotonin into its terminals (Belin et al. 1976; Kan nengiesser et al. 1976 ). The effects of FEN are blocked by 5-HT uptake inhibitors, as in MDMA and PCA (Hek matpanah and Peroutka 1990). These observations sug gest that the carrier-mediated release of serotonin and the inhibition of its reuptake are critical components in the mechanism of these drugs. FEN, FLUOX, and MDMA bind to the serotonin transporter protein with high affinity; the rank order potencies for binding NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO. 4 to the transporter for these agents is FLUOX>FEN = MDMA (Poblete et al. 1989) .
The similar actions of FEN, FLUOX and MDMA on serotonin transporter binding suggest they may pos sess common effects upon other serotonergic param eters, such as monoamine oxidase activity, in vitro. The present report examines the effects of both enantiomers of MDMA on catabolism of [3H]-serotonin and p4C] phenethylamine by rat brain monoamine oxidase in vitro. In addition, we compared the effects of fluoxe tine (FLUOX) and fenfluramine (FEN) to MDMA on rat brain MAO activity. Our results suggest that inhibition of MAO-A by MDMA may contribute to an accumula tion of extracellular 5-HT. The inhibition of MAO-B ac tivity by FLUOX may increase intracellular 5-HT, whereas the actions of FEN do not appear to involve MAO inhibition.
MATERIALS AND METHODS
Male Sprague-Dawley rats weighing 200 to 250 g (Ta conic Farms, Germantown, NY) were housed two per cage and given free access to food and water. The animals were maintained on a 12-hour light/dark cy cle. Animals were euthanized with C0 2 and decapi tated according to a protocol approved by the NYU An imal Welfare Committee. Brains were rapidly removed and placed on ice in 0.32 mollL sucrose. After removal of the cerebellum, brains were homogenized in 10-fold volume/weight in 0.32 mollL sucrose using 10 strokes with a Teflon/glass homogenizer. P1 pellets were pre pared by sedimentation of homogenates at 800 x g for 10 minutes at 2°C in a Sorvall RC5C centrifuge (Sorvall Instruments, DuPont, Chadds Ford, PA). Supernatants were resedimented at 14,000 xg at 2°C for 15 minutes to obtain a crude mitochondrial P 2 pellet. Resultant pellets were resuspended in 500 ilL 0.32 mollL sucrose and stored at -70°C until use.
Prior to the MAO assay, homogenates were thawed and brought up to lOx volume/original weight 0.01 mollL sodium phosphate buffer (PB), pH 7.4 and dialyzed to remove endogenous monoamines by a modiflcation of the method described by Patterson, et al. (1973) . Briefly, homogenates were dialyzed in 2 mL aliquots using 3500 mw cutoff dialysis tubing (Spec trap or) against 0.01 mollL PB, pH 7.4 at 4°C for 2 hours with three successive changes of 1L buffer. MAO as says were performed immediately following this di alysis.
Monamine oxidase activity was assayed using Jlmolll to 50 Jlmolll (50.8 mCi/mmol, 0. 1 JlCi/ml, New England Nuclear, Boston, MA) served as substrate for MAO-B. The assay procedure was a modifIcation of the method described by Pintar et al. (1981) and Lan et al. (1989) . 
Additive Effects
To determine whether MDMA and FLU OX share a common mechanism for MAO inhibition, homogenates were treated with FlUOX and ( + ) MDMA in combina tion at their ICso or at 2 x ICso concentrations individu ally. Radiolabeled substrate was added and MAO ac tivity was assayed as described above.
To determine nonspecifIc counts, a set of samples was preincubated with 1 mmolll clorgyline or 1 mmolll deprenyl, as appropriate, for 10 minutes at 37°C. Pro tein concentrations of homogenates were determined by the method of lowry et al. (1951) with bovine se rum albumin (Sigma Chemical Co., St. louis, MO) as standard. Protein detection was determined at 540nm absorbance using a Titertek Multiskan spectrophotom eter (EFlAB, Helsinki, Finland) .
Analysis of data was conducted by employing Stu dent's two-tailed t-test for two-sample comparisons. One-way analysis of variance (ANOV A) followed by Tukey post hoc analysis was performed for multisam pIe comparisons (SYSTAT, Evanston, Il). ICso values and Hill coefficients of concentration-response curves were determined by computer-assisted curve-fitting to a logistical equation (SigmaPlot 4.1, Jandel ScientifIc, San Rafael, CA). Kinetic constants for both subtypes of MAO were determined by the analysis of Lineweaver Burk plots. 2.08 ± 0.03 1.72 ± 0.20
28.3 ± 5.0* * No signifIcance was determined between (+ ) and ( -) MDMA with Student's two-tailed t-test.
Values reported here represent the average of three experiments, plus or minus the standard error of the mean. MDMA. All data points represent the average of three ex periments. NonspecifIc values (0.18 nmoles product/mg protein-minute) were subtracted from total activity. Error bars represent the standard error of the mean.
RESULTS
In order to establish the kinetic parameters of MAO ac tivity in this assay system, saturation studies were per formed for MAO-A and MAO-B. MAO-A activity had a Vmax of 2.08 nmoles product/mg protein-minute and a KM of 100 J,lmollL ( Figure 1 , Table 1 ). For MAO-B, a
Vmax of 1.72 nmoles product/mg protein-minute with a KM value of 20 J,lmollL was observed (Figure 2 , Ta ble 1). Both enzyme assay systems were responsive to the appropriate monoamine oxidase inhibitors; clorgy line with a Ki for MAO-A of 0.5 nmollL and deprenyl with a Ki for MAO-B of 1 nmollL. Once these parameters were established, the effects of both enantiomers of MDMA were tested on MAO-A. A different KM but no change in V max was observed for MAO-A (Figure 1 ) with increasing concentrations of MDMA, indicative of a competitive inhibition. No stereospecmc effect was observed (Table 1) , that is ( + ) MDMA had a Ki value of 22.0 J,lmollL against seroto nin as substrate and ( -) MDMA has a Ki value of 28.3 J,lmollL (Table 1) . A competitive inhibition of MAO-A was seen by both enantiomers of MDMA.
The effects of both enantiomers of MDMA were de termined for MAO-B, the subtype of MAO localized within serotonergic neurons. MDMA produced a differ ent type of inhibition with MAO-B than was observed for MAO-A (Figures 1, 2) . In the case of MAO-B, both the V max and KM of the enzyme were changed by a range of MDMA concentrations; 10, 50, 100, and 500 J,lmollL. At the highest concentrations, 1 mmollL, the V max remained the same whereas KM has changed. The change in both the V max and KM shows a mixed-type (Table 2) show a rank order potency of MDMA>FLUOX>FEN (ICso were 44, 130, and 440 J,lmollL, respectively). The ICso of ( -) MDMA for MAO-A was 56 J,lmollL (Table 2) .
A similar study was performed for MAO-B with the drugs at the same concentrations as the MAO-A experi ment. A representative curve obtained from the aver age of three experiments for FEN, FLUOX, and (+) MDMA had Hill coefficients of 1.13, 1. 12, and 0.8182, respectively (Figure 4) . Table 2 FLUOX showed a 60% greater inhibition of MAO-B than MAO-A activity, with an ICso of 80 J.1moliL for MAO-B. FEN showed poor inhibition of both MAO-A and MAO-B.
The additive effects of MDMA and FLUOX were tested. In this set of experiments, each drug was added to homogenates at its ICso or 2 x ICso. Another group had homogenates receiving a combination of both drugs at their respective ICso values. In this way, we were able to test whether MDMA and FLUOX share a com mon mechanism for MAO-A and -B inhibition. A com bination of FLUOX and MDMA at their ICso did not in hibit MAO-A or MAO-B activity more than either drug alone at an equivalent concentration, which is indica tive of a common mechanism for MAO inhibition (Ta ble 3, Table 4 ).
DISCUSSION
Amphetamine has been reported as a competitive in hibitor of MAO-A activity (Mantle et al. 1976 ) and a mixed inhibitor of MAO-B, that is, both the Vrnax and KM are changed (Pearce and Roth 1985) . The results of this study show MDMA acts as a competitive inhibitor of MAO-A activity (see Results, Figure 1) , whereas a mixed pattern of inhibition was observed for the MDMA inhibition of MAO-B (Figure 2) . The kinetics of MAO-A and -B inhibition by MDMA reported here are there fore consistent with those previously described for am phetamine. A nine-fold difference was observed in the ICso of MDMA for MAO-A and MAO-B activity, show ing a selective potency of MDMA for MAO-A in rat brain homogenates (see Results, Figures 3 and 4 , Table  2 ). This finding is consistent with studies showing the in vitro inhibition of MAO-A by amphetamine (Mantle et al. 1976 ) and its analogue, PCA (Fuller et al. 1965) . A selective potency for the inhibition of the A subtype was also observed in vivo in rat brain homogenates 25 hours after the animals were injected with ampheta mine followed by phenelzine, a nonselective MAO in hibitor (Miller et al. 1980) . The inhibition of MAO-A by amphetamine was found to be stereoselective for the ( + ) enantiomer in previous studies by other investigators (Mantle et al. 1976). We observed no signifIcant difference between both enantiomers of MDMA with respect to oxidative deamination of serotonin and phenethylamine by monoamine oxidase (see Results, Table 1 ). This is in contrast to reports of a stereospecifIcity for MDMA on dopamine and serotonin release from striatum (John son et al. 1986; Schmidt et al. 1987) . However, the ob servation that MDMA appears to lack stereospecifIcity for MAO inhibition is consistent with many of the acute properties of this drug both in vivo and in vitro. Re lease of serotonin observed in 3H-serotonin-Ioaded rat hippocampal slices superfused with either enantiomer of MDMA did not show any signifIcant stereoselectivity (Johnson et al. 1986 ). Treatment with both enantiomers of MDMA resulted in a decrease in rat striatal indoles in vivo 3 hours after injection. A nonstereoselective, acute depletion of serotonin following MDMA treat ment in vivo was observed in rat cortex (Schmidt 1987) . Finally, both the optical antipodes of MDMA were po tent inhibitors of 3H-serotonin uptake into rat hip pocampal synaptosomes (Steele et al. 1987) . The abil ity of MDMA to inhibit MAO-A would result in high extracellular levels of 5-HT.
Monoamine oxidase A is an enzyme whose preferred substrate is serotonin (Garrick and Murphy 1982) and is localized in dopaminergic neurons (West lund et al. 1985) . Serotonin has recently been reported to promote the release of DA through the dopamine transporter by an exchange-diffusion mechanism (Ja cocks and Cox 1992) . This effect would be enhanced by an increased level of 5-HT resultant from an inhibition of MAO-A activity.
Fenfluramine and MDMA share many neurophar macologic characteristics. Both drugs bind to the sero tonin transporter, with a similar affinity (Poblete et al. 1989) . MDMA and FEN both release serotonin (E.C.so = 2.92 and 7.90 IlmollL, respectively, Berger et al. 1992; Borroni et al. 1983; Buczko et al. 1975; Johnson et al. 1986; Kannengiesser et al. 1976; Schmidt et al. 1987) , with FEN being more potent. In contrast, MDMA ap pears to be slightly more potent than FEN at inhibition of reuptake (0.42 IlmollL, Steele et al. 1987 and 0.876 IlmollL, Borroni et al. 1983, respectively) . Finally, both drugs are toxic to serotonergic neurons (Appel et al. 1990; Azmitia et al. 1990; Battaglia et al. 1987 Battaglia et al. , 1988 (Gu 1993) and in vivo (Sotelo and Zamora 1978) . The fact that MDMA has greater toxicity is not due to its ability to induce release or bind to the serotonin transporter. However, a comparison between MDMA and FEN on MAO activity in this study showed MDMA to be ap proximately ten times more potent than FEN in the in hibition of MAO-A (see Results, Table 2 ). The inhibi tion of MAO-A may be a crucial variable for induced fIber degeneration. In support of this hypothesis, PCA, which is a more potent serotonergic toxin than MDMA (Gu 1993; Mamounas and Molliver 1988; O'Hearn et al. 1988 ) has a roughly 20-fold higher affinity for MAO A than MDMA (Ki values of 1.33 IlmollL, Fuller 1966 vs. 22 IlmollL, this study).
Fluoxetine is a lipophilic, serotonin uptake blocker that is found in subcellular fragments prepared from brain tissue of FLUOX-treated rats (Caccia et al. 1990 ). Therefore, FLUOX may enter the cell and interact with monoamine oxidase. The ICso of FLU OX was com pared to that of MDMA and FEN with respect to MAO inhibition; the ICso value of FLUOX for MAO-A was nearly three times higher than that of MDMA (see Results, Table 2 ). Interestingly, the ICso of FLU OX for MAO-B, the subtype localized within serotonergic cells, was 80 IlmollL, a nine-fold difference from the ICso of MDMA.
Finally, the additive properties of FLUOX and MDMA were tested on MAO activity (Results, Table  3, Table 4 ). Since both compounds bind to the seroto nin transporter, we examined whether they share a common site for MAO inhibition. The addition of both drugs at their ICso s produced effects that were equiva lent to each drug on its own. We interpret this fInding to be indicative of a competition of both compounds for the same site on MAO-A and MAO-B, respectively (Results, Table 3, Table 4 ).
In summary, these studies show that MDMA pref erentially inhibits MAO-A in a reversible, non stereo specifIc manner. Fluoxetine is signifIcantly more potent than MDMA in the inhibition of MAO-B, whereas FEN does not signifIcantly affect rat brain MAO-A or MAO B activity. Like PCA, the greater toxicity of MDMA (Gu 1993 ) may be related to its ability to produce high lev els of extracellular 5-HT by stimulating release, inhibit ing reuptake and blocking the catabolism of serotonin by MAO-A. The therapeutic actions of Prozac may in-volve a selective inhibition of MAO-B, which would re sult in a greater amount of 5-HT available for release. Finally, FEN has only weak effects on MAO-A and MAO-B activity.
